Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen: Jan 31, 2008

Premium
Qiagen this week announced the release of the Allstars Hs Cell Death Control siRNA, which targets ubiquitous human cell survival genes.
 
“Transfection of this siRNA blend results in a high degree of cell death which is visible by light microscopy,” the company said. The siRNA can be ordered in tubes in 1-nmol, 5-nmol, or 20-nmol amounts, or in 96-well plates in 1-nmol, 0.25-nmol, or 0.1-nmol amounts.
 
The company also released the FlexiPlate siRNA Gene Family Lists, which are siRNA sets that enable RNAi screening of 54 human gene families. 
 
Controls, scales, and plate layout can be chosen to suit individual requirements, the company noted.
 
Lastly, Qiagen has launched the Whole Human Genome siRNA set v4, the Human Druggable Genome siRNA set v4, and subsets for GPCRs, phosphatases, and kinases.
 
The sets are provided in various scales and formats, including individual or pooled siRNAs.
 
The Human Whole Genome siRNA set targets 19,121 human genes, and can be supplemented with a set targeting 5,318 predicted additional genes. The Human Druggable Genome siRNA set targets 6,961 genes of potential therapeutic value, which the subsets target 490 GPCR genes, 696 kinase genes, or 205 phosphatase genes.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.